前列腺癌雄激素靶向治疗:实践演变与未来考量
本文综述晚期前列腺癌雄激素剥夺治疗(ADT)的最新临床方案与患者管理最佳实践。现代检测显示双侧睾丸切除后血清睾酮约15 ng/dL,低于历史去势标准50 ng/dL;将睾酮降至<20 ng/dL可改善生存并延缓进展。新型抑制雄激素信号药物联合传统ADT可将睾酮活性抑制至接近零并显著改善生存。
要点
- 双侧睾丸切除后血清睾酮约15 ng/dL,低于历史去势标准50 ng/dL。
- 将睾酮降至<20 ng/dL可改善患者生存并延缓疾病进展。
- 治疗中需常规监测睾酮与PSA以确保睾酮抑制持续有效。
核心结论
- 现代检测技术显示双侧睾丸切除后血清睾酮约15 ng/dL,低于历史去势定义T<50 ng/dL。
- 证据表明将睾酮降至<20 ng/dL可改善患者生存并延缓疾病进展。
- 新型抑制雄激素信号药物联合传统ADT可将睾酮活性抑制至接近零并显著改善患者生存。
研究设计与样本
- 本文为综述,讨论ADT最新选项的临床特征、晚期前列腺癌患者管理最佳实践及未来治疗方向。
主要发现
- 双侧睾丸切除后血清睾酮约15 ng/dL,而历史去势定义为T<50 ng/dL。
- 将T降至<20 ng/dL可改善生存并延缓疾病进展。
- 治疗全程除PSA外常规监测T对确保睾酮抑制持续有效很重要。
- 新型抑制雄激素信号药物联合传统ADT可将T活性抑制至接近零并显著改善生存。
关键数值与推荐
- 历史去势定义:血清睾酮<50 ng/dL。
- 双侧睾丸切除后血清睾酮约15 ng/dL。
- 将睾酮降至<20 ng/dL可改善生存并延缓进展。
临床怎么用
- 治疗全程应常规监测睾酮与PSA以确保睾酮抑制持续有效。
- 若患者未达到充分睾酮抑制,可考虑切换单药治疗。
- 根据患者生活方式、合并症、危险因素及治疗耐受性考虑间歇性与持续性ADT。
- 个体化ADT方案时应考虑ADT的启动时机与持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Androgen deprivation therapy (ADT) is foundational in the management of advanced prostate cancer (PCa) and has benefitted from a recent explosion in scientific advances. These include approval of new therapies that suppress testosterone (T) levels or inactivate its function, improvements in diagnostic and assay technologies, identification of lower therapeutic targets for T, discovery of the relevance of germline genetic mutations and identification of the benefits of sequential and combination therapies. METHODS: This review discusses the clinical profiles of the most up-to-date options for ADT, best practices for managing patients with advanced PCa and future directions in therapy. RESULTS AND CONCLUSIONS: Modern assay technologies reveal that bilateral orchiectomy results in a serum T level of approximately 15 ng/dL as compared to the historical definition of castration of T < 50 ng/dL. Evidence shows that lowering T levels to <20 ng/dL improves patient survival and delays disease progression. Routine monitoring of T in addition to prostate-specific antigen throughout treatment is important to ensure continuing efficacy of T suppression. New drugs that inhibit androgen signaling in combination with traditional ADT suppress T activity to near zero and have significantly improved patient survival. When personalizing ADT regimens physicians should consider a number of factors including initiation and duration of ADT, monitoring of T levels and PSA, the possibility of switching monotherapies if a patient does not achieve adequate T suppression, and consideration of intermittent vs. continuous ADT according to patients' lifestyles, comorbidities, risk factors and tolerance to treatment.
引用
- Crawford ED, Heidenreich A, Lawrentschuk N, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2018. PMID: 30131604. doi:10.1038/s41391-018-0079-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。